Comparing chemo-immunotherapy with or without radiation before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a short course of radiation to a combination of chemotherapy and an immunotherapy drug (called a PD-1 inhibitor) before surgery helps shrink tumors and improve outcomes for people with upper stomach or gastroesophageal junction cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have adenocarcinoma (a common type of cancer) in the upper stomach or where the stomach meets the esophagus.
- The cancer is locally advanced, meaning it has grown into or near nearby tissue but has not spread to distant organs.
- You have not had chemotherapy, radiation, or immunotherapy for this cancer before.
- You are in generally good health, can do most normal activities, and have adequate organ function (heart, liver, kidneys, blood cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted radiation treatment during surgery to the usual combination of immunotherapy and chemotherapy helps people with advanced stomach cancer before they have surgery to remove the tumor. The goal is to see if this extra treatment can improve outcomes.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This trial tests whether adding immunotherapy to chemotherapy after surgery for stomach or gastroesophageal junction cancer helps prevent the cancer from coming back. It is for people whose cancer is HER2-negative and who have had the tumor completely removed.
This study compares two treatment plans after surgery for stomach cancer: chemotherapy alone versus chemotherapy plus immunotherapy (a treatment that helps your immune system fight cancer). The goal is to see which plan is better at preventing cancer from returning.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.